(Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it. The U.S. Food and Drug Administration said the risk is already described in the warnings and precautions section of the label for both drugs. Now the information will be placed in a black box, indicating the most serious type of risk. (Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment